Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(21)
•••
Comment by Sinbobon May 18, 2012 12:14pm
206 Views
Post# 19925841

RE: Sellers

RE: Sellers

The sellers know this....it is not-for-profit selling in my opinion...pick your own reasons. OR, it is part of the latest round of fund liquidation seen in other sectors whereby there have been large redemptions forciing funds too cover losses. However, the volume is so small that I hardly suspect that. Wait a minute! It's small retailers selling to buy into facebook! That's it! Other guesses are equally welcomed.

Side note to show how ridiculous the markets are...Facebook is below 900 other companiies trading in the US with respect to income...and in the top 10 re capitalization as of now. Bono just became a billionare because he owns over 2% of Facebook...of course he holds other investments, like Irish real estate. How many of us actually read the ads on Facebook?

I like our chances with BTI...I hold no fantasies of ever becoming a rock star. Some of you may be young and talented enough to still have them.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities